Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Smittysixty Nov. 15 at 1:45 AM

$PPBT Looky what we have here. Virtu Financial just showed up with 48k. One of the world’s top market makers. High-frequency, dark pool access, global liquidity sniper. They don’t invest. They position — where volatility meets upside. Why now? Low float. Suppressed price. And a biotech platform sitting on unreleased NT‑219 data. Virtu doesn’t chase hype. They trade before the rerate.

1 · Reply

YamiDawg Nov. 15 at 1:14 AM

$PPBT Ahh another Red Day. Gotta get a green one soon. Playing the odds. Not the charts.

0 · Reply

Smittysixty Nov. 15 at 1:00 AM

$PPBT Citadel isn’t retail. They’re the house. Market maker for 40% of U.S. trades. Multi‑strategy hedge fund with $50B+ AUM. Access to dark pools, volatility models, and institutional flow. They just dropped 41K shares into $PPBT. Not a hedge. Not a fluke. That’s positioning before the rerate..

0 · Reply

Stocksavior14 Nov. 15 at 12:11 AM

$PPBT this is the paid pumping permabulls in a nutshell… which proves how they aren’t actual investors because they don’t care about value, only Minor Green Day’s that they can use to pump or pretend the stock is bullish because if they actually cared about value, they wouldn’t be bullish unless the stock was over $30 since most need that or WAY MORE just to break even

0 · Reply

St0ckPwn Nov. 14 at 10:08 PM

$PPBT ah yes the fund that has billions under management managed to throw a measly 20k in here 😂 nearly 4x less than what I put in Shiver me timbers

0 · Reply

Purplepayday Nov. 14 at 10:07 PM

$PPBT Oh, we got Citadel also🤗 Are they going long to hedge against their short position … 🤔 Nah, Citadel isn’t shorting 😬

0 · Reply

Smittysixty Nov. 14 at 9:42 PM

$PPBT Citadel in for 41k Spin that one FUD Patrol

0 · Reply

Purplepayday Nov. 14 at 9:08 PM

$PPBT closing 3% red …… Ven Moon 🤔

1 · Reply

melissascrookedtooth Nov. 14 at 9:08 PM

$PPBT "the CAPTN-3 tri-specific construct are only beginning to garner attention" 🤥 same as it ever was

1 · Reply

Purplepayday Nov. 14 at 7:53 PM

.. it looks like the tutes is loosing interest in $PPBT … Damn, I knew that i shouldn’t have been listening to Shitty 🙄

0 · Reply

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 7:33 AM EDT - 16 days ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 20, 2025, 4:00 PM EDT - 25 days ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Sep 5, 2025, 4:00 PM EDT - 2 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 7:00 AM EDT - 3 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 4 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 5 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 6 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 6 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 7 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 8 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 9 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Feb 14, 2023, 7:01 AM EST - 2 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Smittysixty Nov. 15 at 1:45 AM

1 · Reply

YamiDawg Nov. 15 at 1:14 AM

$PPBT Ahh another Red Day. Gotta get a green one soon. Playing the odds. Not the charts.

0 · Reply

Smittysixty Nov. 15 at 1:00 AM

0 · Reply

Stocksavior14 Nov. 15 at 12:11 AM

0 · Reply

St0ckPwn Nov. 14 at 10:08 PM

$PPBT ah yes the fund that has billions under management managed to throw a measly 20k in here 😂 nearly 4x less than what I put in Shiver me timbers

0 · Reply

Purplepayday Nov. 14 at 10:07 PM

$PPBT Oh, we got Citadel also🤗 Are they going long to hedge against their short position … 🤔 Nah, Citadel isn’t shorting 😬

0 · Reply

Smittysixty Nov. 14 at 9:42 PM

$PPBT Citadel in for 41k Spin that one FUD Patrol

0 · Reply

Purplepayday Nov. 14 at 9:08 PM

$PPBT closing 3% red …… Ven Moon 🤔

1 · Reply

melissascrookedtooth Nov. 14 at 9:08 PM

$PPBT "the CAPTN-3 tri-specific construct are only beginning to garner attention" 🤥 same as it ever was

1 · Reply

Purplepayday Nov. 14 at 7:53 PM

.. it looks like the tutes is loosing interest in $PPBT … Damn, I knew that i shouldn’t have been listening to Shitty 🙄

0 · Reply

Smittysixty Nov. 14 at 6:53 PM

$PPBT Approaching insider‑level pricing. My average keeps sliding lower — no complaints. I’m planted right here until we see that 100mg NT‑219 cohort. Silence isn’t weakness. It’s leverage.

1 · Reply

Stocksavior14 Nov. 14 at 6:00 PM

$PPBT the best part about this, is that @Duediligence20 blocked me when I was trying to warn everyone about the BEARISHNESS HERE!!! So yes, he was GULLIBLE… he believed the INSANE theories. 3 years of an NDA while stock reverse splits, dilutes, and crashes?🤦🏼‍♂️ But it’s interesting he wrote a very bearish post but still puts a bullish tag LOL🤦🏼‍♂️🤦🏼‍♂️🤣🤣 All the permabulls deserve every bit of loss for how much they attacked bearish people who only spread COMMON SENSE

0 · Reply

LuckyBoy27 Nov. 14 at 5:46 PM

$PPBT Stupid mgt post some useless posters when ever they need to raise money or bonus . Just they rearrange the drugs order in PPT to show off . They should be jailed for cheating investors

1 · Reply

Purplepayday Nov. 14 at 4:52 PM

$PPBT Sad that Purple Biotech only can cure Cancer 🥺 https://stocktwits.com/news-articles/markets/equity/merck-to-buy-cidara-in-9.2-billion-dollar-deal/cLPQJxLRE44

0 · Reply

Purplepayday Nov. 14 at 4:33 PM

$PPBT Wonder how many people he have blocked during his time here because they where Bearish 🤔

0 · Reply

Duediligence20 Nov. 14 at 4:17 PM

$PPBT Wish this company would just admit it’s a fraud and fold. I spent a good amount of 4 1/2 years here and hundreds of thousands of dollars believing their bullshit trials, worldwide patent registrations, and miracle molecule bullshit. Was I gullible? I guess so but the fraudulent reporting was very convincing. I believed for three years the company was under an NDA only to find out that was bullshit. Just remember the market has a good way of attaching value and in this case they have been spot on.

0 · Reply

Purplepayday Nov. 14 at 3:47 PM

$PPBT HERO OR ZERO

0 · Reply

Purplepayday Nov. 14 at 3:37 PM

$PPBT i found an early picture of Dr_Him making drawings with only two colors…… Yes, before he became an expert in algo’s and candles 👍

0 · Reply

Purplepayday Nov. 14 at 3:04 PM

$PPBT .. The only catalysts in sight is that not only the management get the option to buy shares a $0.60 🤗 But, they will probably lower their options at the meeting…. And get enough votes for it 👍

0 · Reply

Shullders Nov. 14 at 2:57 PM

$PPBT Maybe they will partner with a high school for CM24 🤦🏼‍♂️. This is nothing but a can kicking dilution monster, no catalysts in sight

0 · Reply

Stocksavior14 Nov. 14 at 2:22 PM

$PPBT 🤣🤣🤣 oh they will get it. And then continue diluting and reverse splitting while the permabulls jump for joy

0 · Reply

St0ckPwn Nov. 14 at 1:56 PM

$PPBT 😂😂😂 their 2 lead phase 2 candidates are on the back burner. Years wasted.

0 · Reply

Market Cap	9.51M
Revenue (ttm)	0.00
Net Income (ttm)	-7.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	185,600
Avg Vol	9,088,556
Day's Range	N/A - N/A
Shares Out	12.85M
Stochastic %K	6%
Beta	0.64
Analysts	Sell
Price Target	$34.00